Summary | |
---|---|
Symbol | HSD17B13 |
Name | hydroxysteroid (17-beta) dehydrogenase 13 |
Aliases | SCDR9; SDR16C3; short chain dehydrogenase/reductase family 16C, member 3; HMFN0376; NIIL497; 17-beta hydroxy ...... |
Chromosomal Location | 4q22.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Secreted |
Domain |
PF00106 short chain dehydrogenase |
Function |
- |
Biological Process |
GO:0019216 regulation of lipid metabolic process GO:0045834 positive regulation of lipid metabolic process GO:0046889 positive regulation of lipid biosynthetic process GO:0046890 regulation of lipid biosynthetic process |
Molecular Function | - |
Cellular Component |
GO:0005811 lipid particle |
KEGG | - |
Reactome |
R-HSA-73923: Lipid digestion, mobilization, and transport R-HSA-1430728: Metabolism R-HSA-556833: Metabolism of lipids and lipoproteins |
Summary | |
---|---|
Symbol | HSD17B13 |
Name | hydroxysteroid (17-beta) dehydrogenase 13 |
Aliases | SCDR9; SDR16C3; short chain dehydrogenase/reductase family 16C, member 3; HMFN0376; NIIL497; 17-beta hydroxy ...... |
Chromosomal Location | 4q22.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between HSD17B13 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
There is no record. |
Summary | |
---|---|
Symbol | HSD17B13 |
Name | hydroxysteroid (17-beta) dehydrogenase 13 |
Aliases | SCDR9; SDR16C3; short chain dehydrogenase/reductase family 16C, member 3; HMFN0376; NIIL497; 17-beta hydroxy ...... |
Chromosomal Location | 4q22.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of HSD17B13 in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | HSD17B13 |
Name | hydroxysteroid (17-beta) dehydrogenase 13 |
Aliases | SCDR9; SDR16C3; short chain dehydrogenase/reductase family 16C, member 3; HMFN0376; NIIL497; 17-beta hydroxy ...... |
Chromosomal Location | 4q22.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of HSD17B13 in various data sets.
|
Points in the above scatter plot represent the mutation difference of HSD17B13 in various data sets.
|
Summary | |
---|---|
Symbol | HSD17B13 |
Name | hydroxysteroid (17-beta) dehydrogenase 13 |
Aliases | SCDR9; SDR16C3; short chain dehydrogenase/reductase family 16C, member 3; HMFN0376; NIIL497; 17-beta hydroxy ...... |
Chromosomal Location | 4q22.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of HSD17B13. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | HSD17B13 |
Name | hydroxysteroid (17-beta) dehydrogenase 13 |
Aliases | SCDR9; SDR16C3; short chain dehydrogenase/reductase family 16C, member 3; HMFN0376; NIIL497; 17-beta hydroxy ...... |
Chromosomal Location | 4q22.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of HSD17B13. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by HSD17B13. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | HSD17B13 |
Name | hydroxysteroid (17-beta) dehydrogenase 13 |
Aliases | SCDR9; SDR16C3; short chain dehydrogenase/reductase family 16C, member 3; HMFN0376; NIIL497; 17-beta hydroxy ...... |
Chromosomal Location | 4q22.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of HSD17B13. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | HSD17B13 |
Name | hydroxysteroid (17-beta) dehydrogenase 13 |
Aliases | SCDR9; SDR16C3; short chain dehydrogenase/reductase family 16C, member 3; HMFN0376; NIIL497; 17-beta hydroxy ...... |
Chromosomal Location | 4q22.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of HSD17B13 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | HSD17B13 |
Name | hydroxysteroid (17-beta) dehydrogenase 13 |
Aliases | SCDR9; SDR16C3; short chain dehydrogenase/reductase family 16C, member 3; HMFN0376; NIIL497; 17-beta hydroxy ...... |
Chromosomal Location | 4q22.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between HSD17B13 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | HSD17B13 |
Name | hydroxysteroid (17-beta) dehydrogenase 13 |
Aliases | SCDR9; SDR16C3; short chain dehydrogenase/reductase family 16C, member 3; HMFN0376; NIIL497; 17-beta hydroxy ...... |
Chromosomal Location | 4q22.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting HSD17B13 collected from DrugBank database. |
There is no record. |